This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a trial that assigned 59 adults with moderate to severe major depressive disorder to a condition centered on psilocybin or one centered on the selective serotonin reuptake inhibitor escitalopram and compared them over 6 weeks. Both groups received psychological support, and blinding was attempted with a double-dummy design.
It is inaccurate to read the title alone as showing that psilocybin defeated an existing medication. On the prespecified primary outcome, the between-group difference at 6 weeks was not statistically significant. Some secondary outcomes favored the psilocybin group, but without adequate adjustment for multiple comparisons they cannot support a confirmatory conclusion.
Study design
Participants received psilocybin sessions with daily placebo tablets or low-dose psilocybin sessions with daily escitalopram. The primary outcome was 6-week change on a self-report depression scale, and several secondary scales, response and remission, and adverse events were also assessed.
Distinctive subjective effects and side effects from daily medication may have allowed participants to infer their allocation. The 2 conditions did not compare substances alone; session experiences, expectations, psychological support, and daily medication were combined.
Content
The study’s value lies in attempting a comparison that included a standard antidepressant rather than only an inactive placebo. Its exploratory sample of 59, however, was not a large trial designed to establish noninferiority or superiority.
Distinguishing primary from secondary outcomes is fundamental in clinical research. Measuring many scales increases the chance of finding a difference by coincidence, so secondary signals need to be read while preserving the fact that the primary outcome did not differ.
Results
Depressive symptoms improved in both groups. The mean change on the primary scale differed numerically, but it did not meet the prespecified statistical criterion for a significant between-group difference. Several secondary outcomes favored the psilocybin group, but they were interpreted as exploratory.
Types of adverse events differed by condition, and the overall picture needs to include headache, nausea, anxiety, sleep, sexual functioning, and other effects. Results over 6 weeks cannot establish long-term relapse, continued administration, withdrawal, or rare harms.
Limitations
The principal limitations are small size, short duration, a selected population, and functional unblinding. The amount of support in each group, expectations, and participants’ prior medication experience may also have influenced outcomes. Because of multiplicity among secondary measures, interpretations that select only favorable items should be avoided.
One trial does not replace clinical guidelines or establish efficacy and safety in routine care. It also did not evaluate mushroom products.
Many participants applied with an interest in the research and may have differed from patients in routine care in expectations and motivation for selection. The escitalopram assessment period was also short for comparing long-term effects including maintenance treatment.
Safety
Stopping or switching antidepressants can involve withdrawal symptoms and relapse and should not be done through self-judgment. The psilocybin condition also carries risks including acute anxiety, changes in blood pressure, headache, and confusion, and the trial used screening and monitoring.
This page does not decide which treatment is better for an individual or guide ingestion or medication changes. Individual assessment is required for mania, psychotic symptoms, suicide risk, and other factors.
Source and rights
Original source: Carhart-Harris R, et al. Trial of Psilocybin versus Escitalopram for Depression. The New England Journal of Medicine. 2021;384:1402–1411. DOI: 10.1056/NEJMoa2032994.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes study design, primary and secondary results, safety, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.